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Abstract Mipomersen (Kynamro), a second-generation
20-O-methoxyethyl chimeric antisense oligonucleotide
(ASO), inhibits the synthesis of apolipoprotein B (apoB)
and is indicated in the US as an adjunct therapy for
homozygous familial hypercholesterolemia (HoFH) at a
dose of 200 mg subcutaneously (SC) once weekly. The
pharmacokinetic (PK) properties of mipomersen are gen-
erally consistent across all species studied, including
mouse, rat, monkey, and humans. After SC administration,
mipomersen is rapidly and extensively absorbed. It has an
apparent plasma and tissue terminal elimination half-life of
approximately 30 days. Mipomersen achieves steady-state
tissue concentrations within approximately 4–6 months of
once-weekly dosing. It does not exhibit PK-based drug–
drug interactions with other concomitant medications,
either involving competition for plasma protein binding or
alterations in disposition of any evaluated drugs. Further-
more, mipomersen does not prolong the corrected QT
(QTc) interval. There have been no ethnic- or gender-
related differences in PK observed. In clinical trials, both
as a single agent and in the presence of maximal lipid-
lowering therapy, mipomersen has demonstrated signifi-
cant dose-dependent reductions in all measured apoB-
containing atherogenic lipoproteins. Overall, mipomersen
has well-characterized PK and pharmacodynamic proper-
ties in both animals and humans, and is an efficacious
adjunct treatment for patients with HoFH.
Key Points
Mipomersen is an antisense oligonucleotide inhibitor
of apolipoprotein B-100 synthesis, approved in the
US for the treatment of patients with homozygous
familial hypercholesterolemia.
Mipomersen has consistent and well-characterized
pharmacokinetic and pharmacodynamic properties in
both animals and humans.
Mipomersen reduces levels of all apolipoprotein-B
containing atherogenic particles in a dose-dependent
manner as a single agent and in the presence of
maximal lipid-lowering therapy.
1 Introduction
Antisense oligonucleotides (ASOs) are single-stranded
synthetic oligonucleotides, typically comprised of 16–20
nucleotides, which bind to RNA through sequence-specific
Watson–Crick base-pair interactions [1]. Once bound,
ASOs can affect the metabolism of the target RNA by a
number of mechanisms, including degradation via the
recruitment of endogenous RNase H1 [2, 3]. Reduction in
target messenger RNA (mRNA) levels by ASOs that sup-
port the RNase H1 mechanism has proven to correlate
directly with reduction in target protein levels [4, 5].
There is significant growth and maturity in the number
and type of RNA-targeted drugs being studied in clinical
trials today. Most RNA targeted drugs in the clinic today are
single-stranded ASOs that are chemically modified for
enhanced pharmacokinetic (PK) and pharmacodynamic
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(PD) properties, and utilize a chimeric design to support
RNase H1 activity [1]. These modifications include the
phosphorothioate (PS) backbone, where one of the two non-
bridging oxygens of the natural phosphodiester linkage is
replaced with sulfur, and partial sugar modifications using
20-O-methoxyethyl (MOE). The PS modification reduces the
rate of degradation by nucleases, enhances distribution to
tissues by binding to plasma proteins, and also supports
RNase H1 activity when combined with a 20-deoxy sugar
residue. The 20-MOE sugar modification imparts additional
drug stability and also increases the affinity for the target
RNA to achieve up to tenfold greater potency [6].
ASOs are distinguished from other classes of pharma-
ceutical agents by both the mechanism of action and
physical–chemical or pharmaceutical properties. These
distinguishing features provide an opportunity to pursue a
large spectrum of first-in-class or best-in-class therapeutic
agents for molecular targets that are validated but
unreachable by other classes of agents, e.g. small mole-
cules and antibodies, which predominantly target proteins.
Apolipoprotein B (apoB)-100 is a validated molecular
target, where both the gene expression profile and protein
structure function are well-suited for application of the
antisense technology. ApoB is an essential structural
component of low-density lipoprotein (LDL) and its met-
abolic precursor, very-low-density lipoprotein (VLDL) [7].
LDL cholesterol (LDL-C) levels bear a direct relationship
to major cardiovascular events, including death [8–10].
Therefore, reduction in LDL-C is the primary goal for most
lipid-modifying interventions [11, 12]. Individuals with
familial hypercholesterolemia (FH) frequently fail to meet
LDL-C targets while taking the maximum tolerated lipid-
lowering therapy, including high-dose statins, particularly
those who are homozygous [13, 14]. Thus, additional
effective treatments are needed [15, 16].
Mipomersen (Kynamro; Genzyme, A Sanofi Corpora-
tion, Cambridge, MA, USA) is a synthetic second-gener-
ation ASO containing 20 nucleotides complementary to the
coding region of the apoB mRNA, which is approved in the
US as an adjunct to lipid-lowering medications and diet to
reduce LDL-C, apoB, total cholesterol (TC), and non-high-
density lipoprotein cholesterol (non-HDL-C) in patients
with homozygous FH [17, 18]. ApoB and apoB-containing
lipoproteins, such as LDL, and lipoprotein(a) [Lp(a)], are
independent risk factors of cardiovascular disease [19, 20].
Patients with homozygous FH have a marked elevation in
each of these risk factors compared with other high-risk
populations [21]. Further to reductions in LDL-C levels,
mipomersen produced significant reductions in all mea-
sured apoB-containing lipoproteins, including Lp(a), in the
pivotal phase III trial [18].
Mipomersen utilizes a chimeric gapmer design whereby
regions of 2’-O-MOE modified residues (5-mer ‘wings’) on
either end of the molecule flank a central DNA region (10-
mer ‘gap’). This design provides enhanced metabolic sta-
bility and potency, and favorable reductions in non-
hybridization-based toxicities, while supporting RNase
H-mediated reduction of the target mRNA. The preclinical
and clinical PK properties of chimeric second-generation
ASOs have been reviewed previously [22–25]. This article
is an updated review of the PK–PD properties of mipom-
ersen [26].
2 Pharmaceutical Properties of Mipomersen
Mipomersen sodium is a synthetic PS oligonucleotide
sodium salt, 20 nucleotides in length, with the following
sequence: 50-GCCUC AGTCTGCTTC GCACC-30, where
the underlined residues are 20-O-MOE nucleosides and all
other residues are 20-deoxynucleosides (Fig. 1) [17].
Cytosine (C) and uracil (U) bases are modified at the 5
position with a methyl group. The molecular formula of
mipomersen sodium is C230H305N67O122P19S19Na19, and its
molecular weight is 7,594.9 g/mol [17].
For clinical use, mipomersen is formulated in a pre-
filled syringe containing 200 mg of mipomersen sodium in
1 mL of aqueous solution (pH 7.5–8.5) without any added
preservative [17].
Mipomersen is well absorbed from subcutaneous (SC)
injection sites and, once in the systemic or vascular cir-
culation, is loosely bound to plasma proteins and rapidly
taken up by tissues through interactions with cell-surface
proteins and endocytosis without usage of specialized
formulations for delivery [25]. Once taken up by tissues,
mipomersen is slowly eliminated by nuclease metabolism
and, ultimately, excretion of predominantly nuclease
digested metabolites in urine.
3 Translational Pharmacokinetic (PK) Properties
of Mipomersen
3.1 Preclinical PK
Mipomersen has demonstrated consistent absorption, dis-
tribution, metabolism and elimination (ADME) properties
across all animal species studied to date, including mouse,
rat, and monkey [5, 27], which ultimately translate well to
man.
3.1.1 Absorption and Distribution
Following SC administration, mipomersen is rapidly
absorbed from the injection site into the circulation, with
peak plasma concentrations consistently reached within
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3–4 h [27]. Nearly-complete absolute bioavailability was
observed after SC administration in monkeys. Following
either intravenous (IV) or SC administration, mipomersen
plasma concentrations rapidly decline from peak concen-
trations in a multi-exponential fashion—characterized by a
dominant initial rapid distribution phase (half-life of a few
hours or less), followed by a much slower terminal elimi-
nation phase (half-life of several weeks). The apparent
terminal elimination rate in monkey plasma was consistent
with the slow elimination of mipomersen from monkey
tissues, indicating equilibrium between post-distribution-
phase plasma concentrations and tissue concentrations
(Fig. 2) [5]. The partition ratios between liver and post-
distribution plasma levels were similar across animal spe-
cies (approximately 6,000:1), and therefore post-distribu-
tion plasma concentrations are also expected to provide a
surrogate for tissue exposure in humans [5]. Plasma PK
parameter estimates for mipomersen across species (ani-
mals and human) after single-dose IV or SC injection are
provided in Table 1 [27].
For all animal species evaluated, mipomersen distributes
broadly into most tissues, with the exception of the brain,
as is the case with all second-generation ASOs [22, 23].
The major tissues of distribution include liver, kidney,
bone marrow, adipose tissue (cell body but not lipid frac-
tion), and lymph nodes [5, 27].
Mipomersen is extensively bound to plasma proteins
(C85 %) across all species [27], with albumin being the
protein that appears to bind the greatest amount of the drug
in most species, including man. Protein binding to albumin
is of relatively low affinity, and thus prevents loss of drug
to renal filtration but does not prohibit uptake in tissues (Kd
approximately 150 lM) [22]. Plasma protein binding is not
saturated at clinically relevant doses due to the large
capacity of binding to proteins in plasma.
3.1.2 Metabolism
The metabolism of mipomersen to chain-shortened
metabolites within tissues occurs initially by endonucleases
that cleave the molecule in the gap, resulting in the pro-
duction of short oligonucleotides that no longer retain
pharmacological activity and have less binding affinity and
capacity with proteins (Fig. 3). These smaller oligonucle-
otides can be further digested by exonucleases to produce a
cascade of shorter oligonucleotides that is similar across
species [27, 28]. Nucleases are ubiquitously expressed in
most tissues, and therefore explain why potential hepatic
insufficiencies do not incur a measurable effect on the
overall clearance of mipomersen.
Mipomersen is not metabolized by traditional drug-
metabolizing enzymes, such as cytochrome P450 (CYP),
and therefore does not interact with small molecules that
are predominantly cleared through oxidative metabolic
pathways [29].
3.1.3 Elimination
The clearance of mipomersen from tissues is slow in all
species studied and involves both metabolism in tissues
(via nucleases) and predominantly urinary excretion of
both parent drug and its chain-shortened metabolites. The
tissue elimination half-life for mipomersen in mice and rats
was C13 days, and in monkeys ranged from 18 to 35 days,
and were not affected by dose [27]. Urinary excretion of
mipomersen and its chain-shortened metabolites is the
major route of whole-body clearance of the drug. Urinary
excretion of total oligonucleotide (mipomersen ? chain-
shortened metabolites) within just the first 24 h after a
single dose, accounted for only a small percentage of the
administered dose in a mouse, rat, and monkey (less than
'Gapmer' design
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Fig. 1 Structural and molecular
formulae of mipomersen
sodium. The binding site for
mipomersen is located in the
coding region of the apoB
mRNA at position 3249–3268
(Acc. No. NM_000384.1).
Reproduced from Crooke et al.
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10 %), consistent with extensive distribution of the bulk of
mipomersen to tissues after dosing [27].
3.2 Clinical PK Properties
The clinical PK properties of mipomersen (30–400 mg SC
or IV dosing) have been studied and reported from several
phase I, II, and III studies [5, 18, 27, 30–38], and compare
nearly identically with other similar 20-O-MOE second-
generation ASOs [22–25, 39, 40]. The PK characteristics of
mipomersen in humans appear generally consistent with
those observed in animals, again similar to what has been
published for this chemical class of ASOs overall. The
FDA-approved dosing regimen for mipomersen is 200 mg
SC once weekly. This dosing regimen was extensively
studied in four phase III pivotal studies and a respective
phase III extension study [18, 36–38, 41].
The PK properties of mipomersen in humans were ini-
tially evaluated in a randomized, double-blind, placebo-
controlled, dose-escalation phase I study involving volun-
teers with mild dyslipidemia [30]. Summaries of reported
plasma PK parameters from 200 mg IV single dosing and
50–400 mg SC single and repeat (4 weeks of treatment)
dosing are provided in Tables 1 and 2. The study consisted
of a single and multiple SC dose of mipomersen 50, 100,
200 or 400 mg. The multiple-dose phase of this study was
characterized by three alternate-day IV infusions of anti-
sense designed to reach *70 % of hepatic tissue steady-
state levels in the first week, followed by three once-
weekly SC doses. Dose-dependent maximum plasma con-
centrations (Cmax) ranged from 4.8 to 21.5 lg/mL
(50–200 mg) at the end of the 2-h IV infusion. Cmax were
also dose-dependent after SC administration, but approxi-
mately fivefold lower than the equivalent IV dose (range
1.0–2.7 lg/mL). The time of peak concentrations (tmax) of
mipomersen were typically observed 3–4 h after SC dos-
ing. Importantly, IV and SC routes of administration
showed similar plasma area under the concentration–time
curve (AUC), with reported absolute bioavailability (rela-
tive to 2-h IV infusion) that ranged from 54 to 78 %. These
plasma exposure estimates of absolute bioavailability
somewhat underestimate total bioavailability. The terminal
elimination plasma half-life ranged from 23 (±1) days in
Table 1 Plasma pharmacokinetic parameter estimates for mipomersen compared across species [27]
Parameter Mouse Rata Monkey Human
5 mg/kg SC 5 mg/kg IV bolus 4 mg/kg 1-h IV infusion 200 mg 2-h IV infusion
Cmax (lg/mL) 3.8 (0.57) 73.9 (2.4) 39.8 (6.7) 21.5 (4.2)
tmax (h) 0.5 2 min 1 (0.1) 1.98 (0.21)
AUC (lgh/mL) 7.41 27.7 82.0 (19.1) 68.2 (13.5)
ta (h) 0.33 0.39 0.68 (0.19) 1.26 (0.16)
tb (day) NM 4.7
b 16c 31.1 (11.4)d
CLp (mL/h/kg)
e 674 181 51.1 (11.1) 40.9 (5.12)
Vss (L/kg)
e NM 1.0 7.7c 48.3 (14.7)d
Standard deviation of the estimates is shown in parentheses
Reproduced from Yu et al. [27], with permission
AUC area under the plasma concentration–time curve, Cmax maximum plasma concentration, CLp plasma clearance, IV intravenous, SC
subcutaneous, tmax time to reach Cmax, ta distribution half-life, tb terminal half-life, Vss apparent volume of distribution at steady state
a Mipomersen concentrations were measured using cold assay, hybridization ELISA method
b Plasma concentration–time profile seemed triphasic, with a half-life of 2.9 h in the second phase; therefore, this half-life represents the
terminal half-life. Additionally, the terminal half-life may be underestimated because of limited time points
c N = 2
d Determined following SC administration
e CLp/F and Vz/F reported for SC dosing



























Mean Ratio = 5800
Fig. 2 Post-distribution-phase plasma and liver concentrations of
mipomersen in monkeys. Each tissue data point represents average
concentrations in two animals. Note that both plasma and tissue
concentrations decay similarly over time following cessation of
intravenous administration. Reproduced from Yu et al. [5], with
permission
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the 50 mg group to 31 (±11) days in the 200 mg group.
While it appears that the terminal elimination half-life (t)
may increase as dose increases, this is likely an anomaly
owing to the detection limit of the bioanalytical assay and
the concentrations in plasma dropping below detectable
levels at earlier time points at the lowest dose tested.
In another short-term, repeat dosing (3 weeks of treat-
ment), phase I, healthy male and female volunteer study,
three different mipomersen dosing regimens were com-
pared [31]. All three regimens were designed to deliver
approximately 200 mg cumulative dose each week (30 mg
daily vs. 70 mg three times weekly vs. 200 mg once
weekly). With repeated administration, and little to no
accumulation in peak (Cmax) and total (AUC) plasma
exposure measures, no gender differences were observed,
and time-invariant kinetics were observed for all treatment
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Fig. 3 Mipomersen metabolism is similar across species.
a Schematic of mipomersen metabolism by nucleases [26]. b Intact
mipomersen and its metabolites identified in urine by liquid
chromatography–electrospray mass spectrometry [27].
c Representative chromatograms of urine samples collected from
monkeys and humans treated with mipomersen. IS internal standard,
MOE methoxyethyl, i.v. intravenous [27]
Table 2 Mipomersen pharmacokinetic summary from a single and multiple subcutaneous dose-escalation study in healthy human volunteers
[26]
Cohort 50 mg (A) 100 mg (B) 200 mg (C) 400 mg (D)
Dose First Last First Last First Last First Last
n 3 6 3 3 3 6 4 2
AUC(0-48 h) (lgh/mL) 7.01 (0.49) 7.68 (1.8) 14.5 (2.91) 19.6 (2.65) 38.3 (29.8) 35.4 (8.0) 106 (17) 113
Cmax (lg/mL) 1.40 (0.29) 1.0 (0.31) 1.45 (0.83) 2.58 (1.41) 2.73 (1.66) 2.06 (0.95) 7.60 (0.81) 7.15
tmax (h) 2.67 (0.58) 3.75 (2.23) 3.00 (1.00) 3.33 (1.15) 4.17 (3.40) 4.64 (3.97) 4.00 (1.63) 7.50
Apparent distribution t (h) 1.84 (0.49) 3.44 (1.38) 4.22 (2.71) 2.96 (1.30) 3.59 (1.22) 7.60 (2.13) 4.33 (0.49) 5.48
%BAV 69.2 (9.63) 77.0 (12.1) 53.0 (17.2) 74.5 (4.7)
Data are presented as mean (standard deviation), except for cohort D at last dose
AUC(0–48 h) area under the plasma concentration–time curve from time zero to 48 h, Cmax maximum plasma concentration, tmax time to reach
Cmax, t terminal elimination half-life, %BAV plasma bioavailability (%) following subcutaneous administration
Adapted from Crooke and Geary [26]
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regimens. While Cmax and AUC of individual doses were
dose-dependent, the relative bioavailabilities of the 30 mg
once daily and 70 mg three times a week treatments were
similar to that of the reference 200 mg every week treat-
ment based on the post-distribution-phase plasma exposure
measures. This latter observation reflects a comparable
total exposure to mipomersen across treatments, and is
consistent with the post-distribution plasma concentrations
being in equilibrium with tissue concentrations. It also
provides evidence of similar tissue concentrations achieved
with each treatment after 3 weeks.
The PK properties of mipomersen were also investigated
in healthy first-generation Japanese male subjects in a
phase I, single SC dose, dose-escalation study, and com-
pared with previously obtained results from healthy Wes-
tern subjects [32]. Twenty healthy first-generation Japanese
male subjects were enrolled into one of three treatment
cohorts (mipomersen 50, 100 and 200 mg SC). The median
tmax varied between 2 and 3 h. Mean Cmax and AUC values
increased in a dose-dependent manner. The mean PK
exposure measures of mipomersen observed in Japanese
subjects were similar to those previously observed in
Western subjects, supporting the ‘no need for dose
adjustment in the Japanese population’ in future clinical
development.
Additional phase I studies involving drug–drug interac-
tion evaluations with mipomersen are described in Sect. 4.
In multiple randomized, double-blind, placebo-con-
trolled, dose-escalation phase II studies in subjects with
varying degrees of a hyperlipidemia phenotype, the PK
properties of mipomersen as a single agent (50–400 mg/
week) or as an add-on to maximum lipid-lowering therapy
were evaluated [33–35]. The PK characteristics in patients
were shown to be similar to those observed in healthy
volunteers, even when added to maximum lipid-lowering
therapy [34]. In patients receiving weekly doses as mono-
therapy without a loading period (200, 300 and 400 mg/
week dose groups), the plasma trough concentrations
continued to increase throughout the treatment period
consistent with the drug elimination half-life, dose interval,
and time needed to reach steady-state, while Cmax and
AUC were again unchanged over time, supporting time-
invariant kinetics [33]. In patients receiving maximum
lipid-lowering therapy, mipomersen plasma t of approx-
imately 30 days was reported across all dose groups, with
no significant change seen with extension of dosing from 5
to 13 weeks [34].
Furthermore, PK measures were determined in FH
patients. In a randomized, double-blind, placebo-con-
trolled, dose-escalation phase II study in 44 patients with
FH, mipomersen SC doses ranging from 50 to 300 mg/
week (eight doses given over a 6-week treatment period, or
13 doses over 13 weeks at 300 mg) were evaluated and
some PK measures determined [35]. Patients received
stable conventional lipid-lowering therapy for at least
4 weeks and consumed a low-fat diet for at least 8 weeks
before the first dose of the study drug and throughout the
study. Once again, the mean plasma t ranged from 25 to
34 days across the evaluated dose groups.
Finally, PK results have recently been reported from a
phase III, open-label extension study with mipomersen
[41]. In this open-label extension study, 141 patients with
FH were treated with mipomersen 200 mg SC weekly for
up to 2 years. Most patients were reported to achieve
steady-state plasma trough levels during the study, with no
apparent gender differences noted. In this study, the
reported median t was 35.1 days, which is generally
consistent with that reported from phase I and II studies.
4 Drug–Drug Interaction Evaluations
with Mipomersen
Mipomersen was evaluated in vitro for its effect on CYP
enzyme activity using cryopreserved human hepatocytes
[29]. Activity was inhibited by less than 10 % at the con-
centrations tested, including up to 800 lg/mL (*100 lmol/
L), approximately ten times the expected liver tissue con-
centrations. Based on the results of this study, mipomersen is
not considered an inhibitor of CYP1A2, CYP2C9,
CYP2C19, CYP2D6 or CYP3A4. Given that mipomersen
does not interact with CYP enzymes, no clinically relevant
PK interactions were anticipated between mipomersen and
medications such as simvastatin, ezetimibe or warfarin.
This lack of effect in vitro was demonstrated in two
phase I clinical studies [29, 42]. As expected, no clinically
significant PK interactions were observed in the phase I
clinical study which evaluated the effects of co-adminis-
tration of mipomersen (200 mg 2-h IV infusion) with
simvastatin (40 mg oral) or ezetimibe (10 mg oral) [29]. In
this study, ten healthy male subjects were enrolled per
cohort and received a single oral dose of simvastatin or
ezetimibe alone, followed by four 2-h IV doses of mi-
pomersen over an 8-day period, with simvastatin or eze-
timibe being administered again with the last dose of
mipomersen. The AUC from time zero to 24 h (AUC24),
Cmax and t values for mipomersen were similar when
administered alone and in combination with oral simva-
statin or oral ezetimibe, providing evidence that neither
simvastatin nor ezetimibe exhibits a clinically relevant PK
interaction with the disposition of mipomersen. The AUC24
and t values for simvastatin and its metabolite were
similar when administered alone or in combination with
mipomersen. The Cmax for simvastatin when coadminis-
tered with mipomersen was in close agreement with liter-
ature values. No statistically significant differences were
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observed in free or total ezetimibe in tmax, AUC from time
zero to 72 h (AUC72) and t when ezetimibe was admin-
istered alone or in combination with mipomersen. The
observed Cmax values for free ezetimibe when administered
alone or in combination with mipomersen were also similar
to previously reported literature values.
In an open-label, single-sequence, two-period, phase I
study in 18 healthy subjects, coadministration of warfarin
(25 mg orally) with mipomersen (200 mg SC) had no effect
on the PK and PD properties of warfarin [42]. Eighteen sub-
jects were enrolled and received a single oral 25 mg warfarin
dose on day 1 and, after a 7-day washout period, received
200 mg mipomersen SC every other day on days 8–12. They
then received both warfarin and mipomersen concurrently on
day 14. There were no clinically significant changes in the PK
of mipomersen with concurrent administration of warfarin. As
expected, all R- and S- warfarin PK parameters evaluated
(AUC from time zero to the last measurable concentration
[AUClast], AUC from time zero to infinity [AUCinf], Cmax, tmax
and t) were similar when warfarin was given alone or with
mipomersen. Furthermore, mipomersen did not cause any
clinically meaningful differences in international normalized
ratio (INR), prothrombin time (PT) or activated partial
thromboplastin time (aPTT) effects of warfarin.
5 Lack of Corrected QT (QTc) Interval Effects
and Other Cardiovascular Events with Mipomersen
Mipomersen does not prolong the corrected QT (QTc)
interval. This was definitively demonstrated in a random-
ized, double-blind, 4-way, crossover phase I study con-
ducted in 60 enrolled healthy volunteers [43]. The primary
study objective was to assess effects of mipomersen on
ECG following administration as single 200 mg therapeu-
tic (SC) or supratherapeutic (2-h IV infusion) doses. Study
treatments included mipomersen IV/placebo SC, mipom-
ersen SC/placebo IV, moxifloxacin (positive control;
400 mg 2-h IV infusion)/placebo SC, and placebo IV/pla-
cebo SC). The primary endpoint was the time-matched
placebo- and baseline-corrected (DD) QTcF interval. Assay
sensitivity in the study was established from a positive
moxifloxacin response. The effect on cardiac repolarization
[maximum mean (90 % CI) DDQTcF] was just 0.6 ms (-
1.5 to 2.7) and 1.0 ms (-1.2 to 3.2) for the mipomersen
200 mg SC and IV doses, respectively. Mipomersen mean
peak plasma exposure was 3.8-fold higher after IV versus
SC treatment, consistent with the former being used as a
supratherapeutic dose.
In a long-term, open-label study with mipomersen, there
were also no significant changes noted in QTc measure-
ments in patients being treated for up to 2 years [41].
6 Pharmacodynamic Properties of Mipomersen
6.1 Preclinical PD and PK/PD Relationship
In all animal species studied, mipomersen has demon-
strated a dose-, concentration- and time-dependent reduc-
tion of apoB-100 mRNA in the liver, which correlates with
the reduction of apoB-100 lipoprotein and apoB-100 con-
taining lipid particles in the blood [44, 45]. In a human
apoB transgenic mouse model, the relationship between
human apoB hepatic mRNA expression and concentrations











































Fig. 4 Exposure–response relationships between ISIS 301012 trough
plasma concentrations and serum apoB levels (% baseline) in healthy
human volunteers during and following six doses of mipomersen at
200 mg per injection. Trough plasma concentrations of ISIS 301012
were measured at C72 h from the last dose. Data are presented as
mean ± standard error. Arrows represent dosing days. Reproduced
from Yu et al. [5], with permission. apoB apolipoprotein B, i.v.
intravenous infusion, s.c. subcutaneous injection
Mipomersen Pharmacokinetics and Pharmacodynamics 139
reported with estimated EC50 values of 119 ± 15 lg/g in
liver and 18 ± 4 ng/mL in plasma [5]. Furthermore, the
apoB mRNA reductions in human transgenic mice treated
with mipomersen were specific for human apoB mRNA, as
no change in murine apoB mRNA was observed in this
model. Additionally, corresponding reductions in liver
apoB protein, serum apoB protein, LDL-C, and TC were
reported in the animals with reduced hepatic apoB mRNA.
In these experimental evaluations, control ASOs had no
effect on apoB mRNA in the liver, indicating that inhibi-
tion of apoB expression was both target- and sequence-
dependent.
6.2 Clinical PD and PK/PD Relationship
In the first-in-man phase I study conducted in volunteers
with mild dyslipidemia, the 200 mg dose produced an
approximate 50 % reduction in circulating apoB following
4 weeks of treatment. The trough plasma mipomersen drug
concentrations increased during weekly administration and
slowly cleared from plasma with an approximate 31-day
half-life following cessation of dosing. Consistent with the
drug levels of mipomersen, apoB levels decreased during
mipomersen treatment, reaching its nadir shortly after the
last administered dose (Fig. 4) [5]. Upon cessation of
dosing, apoB levels remained low for several weeks and
slowly returned to baseline over several months, consistent
with the slow clearance of the drug. These early data
confirmed animal PK/PD relationships and the under-
standing that drug levels correlate directly with drug
activity.
Mipomersen has a long t, with post-distribution-phase
plasma concentrations best predicting tissue (e.g. liver)
concentrations and therefore pharmacological activity. The
post-distribution (trough) plasma concentration-response
relationships for mipomersen in healthy volunteers,
hypercholesterolemic patients, and hypercholesterolemic
patients taking statins are shown in Fig. 5, and demonstrate
a consistent EC50 of 10–17 ng/mL [26].
In the four previously described phase I and II studies,
the PD properties of mipomersen (30–400 mg/week) were
evaluated [30–35]. These studies included patients
(N = 33) with mild dyslipidemia (who were not on lipid-
lowering medication) [30], patients (N = 50) with mild-to-
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Fig. 5 Plasma concentration-response relationships for mipomersen.
The individual points represent measurements of apoB or mipomersen
in serum of (a) healthy volunteers or (b) phase II studies in
hypercholesterolemic patients in combination with statins or (c) as a
single agent. Reproduced from Crooke et al. [26], with permission.
apoB apolipoprotein B, PD14 14 days after the last dose
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medication) [33], patients (N = 74) with hypercholestere-
mia receiving stable statin therapy [34], and patients
(N = 44) with FH (who were on stable lipid-lowering
medication for at least 4 weeks and a low-fat diet for at
least 8 weeks before the first study dose) [35]. Across all of
these studies, mipomersen produced dose-dependent
reductions in all apoB-containing lipoproteins. Data shown
in Fig. 6 are representative of the dose-dependent and
prolonged effects of mipomersen treatment on apoB and
LDL-C levels over time [33].
Mipomersen was also evaluated in 34 high-risk patients
with hypercholesterolemia who were statin intolerant [46].
In this randomized, double-blind, placebo-controlled phase
II study, patients received mipomersen at 200 mg/week SC
for 26 weeks. As observed across all other study popula-
tions, treatment with mipomersen resulted in significant
reductions in LDL-C (-47 %, p \ 0.001 vs. placebo) and
apoB (-46 %, p \ 0.001 vs. placebo). Patients who were
treated with mipomersen also had significantly lowered
TC, triglycerides, and lipoprotein (a), with no effect on
HDL-C and apo-A1.
Based on the extensive evaluations of dose and drug
plasma concentration-response relationships in phase I and
II studies, a weekly SC dose of mipomersen 200 mg was
selected for phase III evaluations. Four randomized, pla-
cebo-controlled, phase III trials have been conducted in
patients who were taking maximally tolerated doses of
lipid-lowering drugs. In these trials, patients were dosed
weekly with either placebo or mipomersen 200 mg SC for
26 weeks (Table 3) [18, 36–38]. Consistent reductions in
apoB and apoB-containing lipoproteins were observed
across these four phase III trials with this dose regimen.
The four phase III studies enrolled patients with
homozygous FH (N = 51) [18], severe hypercholesterol-
emia (N = 58) [36], heterozygous FH (N = 124) [37] and
severe hypercholesterolemia in patients at high cardiovas-
cular risk (N = 158) [38]. All patients in these four trials
were on maximally tolerated lipid-lowering therapy and
treatment period



















































































Fig. 6 Dose-dependent effects
of mipomersen as a single agent
on (a) apoB and (b) LDL
cholesterol in patients with mild
to moderate hyperlipidemia.
Patients (N = 50) were treated
for 13 weeks with mipomersen
at a dose of 50–400 mg, or
placebo [34]. Data presented are
the median percentage change
from baseline from day 1 to day
175. apoB apolipoprotein B,
LDL low-density lipoprotein
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had an average of more than two prior cardiovascular
events. The percentage change from baseline in LDL-C in
patients treated with mipomersen 200 mg SC weekly ran-
ged from -25 to -37 %, while those treated with placebo
ranged from -5 to ?13 % (Table 3). The effects on LDL-
C, apoB and Lp(a) levels in homozygous FH patients after
26 weeks of treatment with mipomersen compared with
placebo are shown in Fig. 7.
Sustained reductions in LDL-C, apoB, TC, non-HDL-C
and Lp(a) were observed in the corresponding phase III
open-label extension study, which involved 141 patients
with FH [41]. Figure 8 shows the results for apoB and
LDL-C. Five of the patients in this study were treated with
mipomersen 200 mg SC weekly for a mean duration of
48 months (range 41–52 months) [47]. LDL-C decreased
from a mean baseline of 174 mg/dL to a mean of 120 mg/
dL (-31 % vs. baseline, p = 0.003) at last assessment.
Similar reductions also occurred in apoB.
Pediatric patients (age range from 12 to 18 years) with
homozygous FH were also examined separately from the
phase III study population [48]. In this subpopulation,
improvements in LDL-C ranged from -30.8 to -62.0 % in
the mipomersen-treated patients (n = 3), and from -7.9 to
?43.1 % in patients receiving placebo (n = 4). After
completion of the index study, all of the placebo-treated
pediatric patients entered an open-label extension study
and received mipomersen. The efficacy of mipomersen in
these pediatric patients was consistent with that observed in
adult patients.
Finally, mipomersen treatment can result in elevations
in hepatic fat in man with or without increases in trans-
aminases [41]. The effect on liver fat increases does not
appear to be associated with drug concentration but rather a
reciprocal association with the rate and extent of apoB and
LDL-C lowering [30, 37]. This suggests that changes in
lipid excretion from the liver may alter storage and possi-
bly extend to increases in transaminases. Importantly, in
long-term, open-label clinical trials, investigators have
reported that the increases in liver fat observed in some
patients decrease with continued dosing, suggesting that
the liver may adapt to the change in lipid metabolism [41].
7 Summary
Mipomersen, as seen with many 20-O-MOE modified sec-
ond-generation ASOs, has highly predictable PK properties
that are generally consistent across all species studied.
Single- and multiple-dose PK of mipomersen in healthy
volunteers and in patients with FH and non-FH has shown
that mipomersen plasma exposure increases with increas-
ing dose in the range of 30–400 mg, with similar exposures
at equivalent administered SC doses independent of patient
gender, ethnicity, lipidemic state, or concomitant lipid-
lowering drug therapy. Given that mipomersen is not
metabolized by traditional drug-metabolizing enzymes,
such as CYP, it is not surprising that no clinically relevant
PK interactions have been reported. Studies designed to
Table 3 Key results from randomized placebo-controlled phase III clinical trials
% Change from Baseline Drug HoFH [18]
Mipomersen (n = 34)
Placebo (n = 17) [%]
Severe HC [36]
Mipomersen (n = 39)
Placebo (n = 18) [%]
HeFH with CAD [37]
Mipomersen (n = 82)
Placebo (n = 41) [%]
HC at high risk [38]
Mipomersen (n = 101)
Placebo (n = 50) [%]
LDL-C* Mipomersen -25 -36 -28 -37
Placebo -3 ?13 ?5 -5
apoB* Mipomersen -27 -36 -26 -38
Placebo -3 ?11 ?7 -4
Lp(a)* Mipomersen -31 -33 -21 -26
Placebo -8 -2 0 -0
TG** Mipomersen -17 -9 -14 -25
Placebo ?0.4 ?27 ?1 ?11
HDL-C*** Mipomersen ?15.1 ?6 ?3 ?2
Placebo ?3.9 ?3 ?6 ?2
Data shown is based on the analysis of the intent-to-treat population (n), defined as those who received at least one dose of study drug and had at
least one post-baseline LDL-C measurement
apoB apolipoprotein B, CAD coronary artery disease, HC hypercholesterolemia, HDL-C high-density lipoprotein cholesterol, HeFH hetero-
zygous familial hypercholesterolemia, HoFH homozygous familial hypercholesterolemia, Lp(a) lipoprotein(a), LDL-C low-density lipoprotein
cholesterol, TG triglyceride
p-Values (vs. placebo): * p \ 0.001 all populations, ** p \ 0.05 all populations, *** p \ 0.05 in HoFH population
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AB
C
Fig. 7 Mean percentage change
from baseline (week 0) to
primary efficacy timepoint for
(a) LDL cholesterol, (b) apoB,
and (c) Lipoprotein(a). Error
bars indicate 95 % CI.
Reproduced from Raal et al.
[18], with permission. apoB
apolipoprotein B, LDL low-
density lipoprotein
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evaluate PK interactions between mipomersen and warfa-
rin, or between mipomersen and simvastatin or ezetimibe,
have provided additional evidence. Furthermore, no PD
interaction was detected in coadministration of mipomer-
sen with warfarin, as determined by INR, aPTT and PT.
Importantly, mipomersen does not prolong the QTc inter-
val to any clinically relevant extent.
8 Conclusion
Mipomersen is dosed once weekly and follows first-order
PK accumulation based on plasma trough concentrations
associated with overall tissue accumulation and clearance.
The half-life of mipomersen is approximately 31 days in
monkeys and man. Consistent with the PK, a full PD
response as measured by apoB and LDL-C reductions in
homozygous FH patients is achieved between 4 and
6 months, at which time steady-state trough plasma con-
centrations are achieved. Furthermore, chronic studies in
monkeys confirm that no further accumulation in liver
occurs after achievement of steady-state in the 4- to
6-month timeframe [49]. Maximum reduction in apoB and
LDL-C is sustained for up to 4 years with continued dos-
ing. Upon cessation of dosing, the duration of continued
reduction in LDL-C levels follows the slow clearance of
the drug, returning slowly to baseline levels in approxi-
mately 4–6 months.
Mipomersen, a second-generation ASO, has been well-
characterized in terms of PK and PD across preclinical and
clinical studies. Inhibition of apoB synthesis by mipom-
ersen represents a novel, effective therapy to reduce LDL-
C concentrations in patients with hypercholesterolemia
who cannot achieve appropriate lipid concentrations with
current lipid-lowering agents.
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